Combinative Therapy with miR-17-Targeting Mesyl Oligonucleotide and Cisplatin Suppresses Tumour Growth and Extends Survival in Drug-Resistant KB-8-5 Xenografts

Journal of Analytical Science and Technology · Springer Nature · 2026-09-01 · DOI: 10.1134/S1990750826600780

Abstract

Abstract MicroRNA-targeted therapeutics are increasingly recognized as promising molecular adjuvants for conventional chemotherapy, as their ability to remodel multiple resistance-associated pathways may restore drug sensitivity in refractory tumours. Our previous in vitro studies identified the miR-17-targeting mesyl phosphoramidate antisense oligonucleotide µ-17 as a potent cisplatin-sensitizing agent in multidrug-resistant KB-8-5 cells, supporting its in vivo evaluation. Here, we investigated this strategy in a nude mouse xenograft model of human KB-8-5 epidermoid cervical carcinoma. To enhance the translational relevance of the study, the treatment regimen was modelled on current clinical guidelines and comprised five treatment cycles using cisplatin at a dose approximately 30% less than specified in standard clinical protocols. Whereas either µ-17 or cisplatin alone produced only a modest and transient delay in tumour progression, the combination of µ-17+ cisplatin induced a pronounced and durable antitumour response. In this group tumor growth retardation was observed for approximately four weeks after treatment cessation accompanied by a shift in individual responses towards smaller tumour volumes, delayed body-weight loss, and a significant increase in restricted mean survival time. Combination therapy also reduced tumour mitotic activity and decreased the multidrug resistance-associated proteins ZYX, TUBA4A, and SEH1L, consistent with multilevel reprogramming of proliferative and resistance-related pathways downstream of miR-17. Collectively, these findings establish miR-17-targeting oligonucleotide µ-17 as a promising cisplatin-sensitizing adjuvant capable of improving the depth and durability of response in multidrug-resistant tumours while supporting the therapeutic potential of reduced-dose chemotherapy.

Read at publisher →

Similar articles